{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:42:12Z","timestamp":1740109332966,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00059-022-05142-6","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T11:04:18Z","timestamp":1667559858000},"page":"372-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions","\u00dcbersicht \u00fcber Pharmakotherapie auf der Basis von ACE-2 bei COVID-19-Erkrankung: aktuelle Herausforderungen und zuk\u00fcnftige Entwicklungen"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-166X","authenticated-orcid":false,"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6528-2171","authenticated-orcid":false,"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Trama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"5142_CR1","unstructured":"World health organization (WHO) (2022) Situation reports. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed September 2022"},{"key":"5142_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang\u00a0C, Horby\u00a0PW, Hayden\u00a0FG, Gao\u00a0GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470\u2013473","journal-title":"Lancet"},{"key":"5142_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang\u00a0C et\u00a0al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506","journal-title":"Lancet"},{"key":"5142_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02584-5","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, Porta\u00a0R, Pianesi\u00a0L, Ferrara\u00a0F (2021) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-021-02584-5","journal-title":"Ir J Med Sci"},{"key":"5142_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li\u00a0Q et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N\u00a0Engl J Med 382:1199\u20131207","journal-title":"N Engl J Med"},{"issue":"2020","key":"5142_CR6","first-page":"727","volume":"382","author":"N Zhu","year":"2019","unstructured":"Zhu\u00a0N et\u00a0al (2019) A novel coronavirus from patients with pneumonia in China. N\u00a0Engl J Med 382(2020):727\u2013733","journal-title":"N Engl J Med"},{"key":"5142_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.07.937862","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya\u00a0AE et al (2020) Severe acute respiratory syndrome-related coronavirus: the species and its viruses\u2014a\u00a0statement of the Coronavirus study group. Microbiology. https:\/\/doi.org\/10.1101\/2020.02.07.937862","journal-title":"Microbiology"},{"key":"5142_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ajcp\/aqaa029","volume":"153","author":"J Guarner","year":"2020","unstructured":"Guarner\u00a0J (2020) Three emerging coronaviruses in two decades. Am J Clin Pathol 153:420\u2013421","journal-title":"Am J Clin Pathol"},{"key":"5142_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106322","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F (2021) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. https:\/\/doi.org\/10.1016\/j.rmed.2021.106322","journal-title":"Respir Med"},{"key":"5142_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.01.007","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, La Porta\u00a0R, D\u2019Aiuto\u00a0V, Ferrara\u00a0F (2021) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. https:\/\/doi.org\/10.1016\/j.humimm.2021.01.007","journal-title":"Hum Immunol"},{"issue":"2","key":"5142_CR11","first-page":"88","volume":"14","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F, Pelliccia\u00a0C, Granata\u00a0G, La Porta\u00a0R (2020) Cytokine storm and colchicine potential role in fighting SARS-CoV\u20112 pneumonia. Ital J Med 14(2):88\u201394","journal-title":"Ital J Med"},{"key":"5142_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-020-02401-5","author":"F Ferrara","year":"2020","unstructured":"Ferrara\u00a0F, Porta\u00a0R, D\u2019Aiuto\u00a0V, Vitiello\u00a0A (2020) Remdesivir and COVID-19. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-020-02401-5","journal-title":"Ir J Med Sci"},{"issue":"7","key":"5142_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen\u00a0SCJ, Kebriaei\u00a0R, Dresser\u00a0LD (2020) Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40(7):659\u2013671. https:\/\/doi.org\/10.1002\/phar.2429","journal-title":"Pharmacotherapy"},{"key":"5142_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-020-02440-y","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F (2020) Remdesivir versus ritonavir\/lopinavir in COVID-19\u00a0patients. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-020-02440-y","journal-title":"Ir J Med Sci"},{"key":"5142_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111497","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, La Porta\u00a0R, Ferrara\u00a0F (2020) Sacubitril, valsartan and SARS-CoV\u20112. BMJ Evid Based Med. https:\/\/doi.org\/10.1136\/bmjebm-2020-111497","journal-title":"BMJ Evid Based Med"},{"key":"5142_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-022-02265-9","author":"A Vitiello","year":"2022","unstructured":"Vitiello\u00a0A, La Porta\u00a0R, Trama\u00a0U, Ferrara\u00a0F, Zovi\u00a0A, Auti\u00a0AM, Di Domenico\u00a0M, Boccellino\u00a0M (2022) Pandemic COVID-19, an update of current status and new therapeutic strategies. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-022-02265-9","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"5142_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00228-020-02947-4","volume":"76","author":"F Ferrara","year":"2020","unstructured":"Ferrara\u00a0F, Granata\u00a0G, Pelliccia\u00a0C, La Porta\u00a0R, Vitiello\u00a0A (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-coV\u20112 : anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol 76(11):1615\u20131618. https:\/\/doi.org\/10.1007\/s00228-020-02947-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"5142_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.drudis.2021.01.010","volume":"26","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, Pelliccia\u00a0C, Ferrara\u00a0F (2021) Drugs acting on the renin-angiotensin system and SARS-CoV\u20112. Drug Discov Today 26(4):870\u2013874. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.010","journal-title":"Drug Discov Today"},{"key":"5142_CR19","doi-asserted-by":"publisher","first-page":"105579","DOI":"10.1016\/j.ejps.2020.105579","volume":"156","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F (2021) Therapeutic strategies for SARS-CoV\u20112 acting on ACE\u20112. Eur J Pharm Sci 156:105579. https:\/\/doi.org\/10.1016\/j.ejps.2020.105579","journal-title":"Eur J Pharm Sci"},{"key":"5142_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz\u00a0D (2020) Angiotensin receptor blockers as tentative SARSCoV\u20112 therapeutics. Drug Dev Res 81:537\u2013540","journal-title":"Drug Dev Res"},{"issue":"2","key":"5142_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming\u00a0I, Timens\u00a0W, Bulthuis\u00a0M, Lely\u00a0A, Navis\u00a0G, van Goor\u00a0H (2004) Tissue distribution of ACE\u20112 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J\u00a0Pathol 203(2):631\u2013637","journal-title":"J Pathol"},{"key":"5142_CR22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang\u00a0H, Penninger\u00a0JM, Li\u00a0Y, Zhong\u00a0N, Slutsky\u00a0AS (2020) Angiotensin-converting enzyme 2 (ACE-2) as a\u00a0SARS-CoV\u20112 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46:586\u2013590","journal-title":"Intensive Care Med"},{"issue":"7408","key":"5142_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature11228","volume":"487","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto\u00a0T, Perlot\u00a0T, Rehman\u00a0A, Trichereau\u00a0J, Ishiguro\u00a0H, Paolino\u00a0M et al (2012) ACE\u20112 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487(7408):477\u2013481","journal-title":"Nature"},{"key":"5142_CR24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.bbrc.2003.11.054","volume":"312","author":"X Xiao","year":"2003","unstructured":"Xiao\u00a0X, Chakraborti\u00a0S, Dimitrov\u00a0AS, Gramatikoff\u00a0K, Dimitrov\u00a0DS (2003) The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 312:1159\u20131164","journal-title":"Biochem Biophys Res Commun"},{"key":"5142_CR25","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"F Li","year":"2005","unstructured":"Li\u00a0F, Li\u00a0W, Farzan\u00a0M, Harrison\u00a0SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864\u20131868","journal-title":"Science"},{"issue":"5","key":"5142_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1714\/3343.331227","volume":"21","author":"P Verdecchia","year":"2020","unstructured":"Verdecchia\u00a0P, Reboldi\u00a0G, Cavallini\u00a0C, Mazzotta\u00a0G, Angeli\u00a0F (2020) ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus. G\u00a0Ital Cardiol 21(5):321\u2013327.  https:\/\/doi.org\/10.1714\/3343.331227","journal-title":"G Ital Cardiol"},{"key":"5142_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106322","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F (2021) Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. Respir Med. https:\/\/doi.org\/10.1016\/j.rmed.2021.106322","journal-title":"Respir Med"},{"key":"5142_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0900-0","author":"R Satou","year":"2018","unstructured":"Satou\u00a0R, Penrose\u00a0H, Navar\u00a0G (2018) Inflammation as a\u00a0regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep. https:\/\/doi.org\/10.1007\/s11906-018-0900-0","journal-title":"Curr Hypertens Rep"},{"key":"5142_CR29","doi-asserted-by":"publisher","DOI":"10.4081\/itjm.2020.1435","author":"F Ferrara","year":"2020","unstructured":"Ferrara\u00a0F, Vitiello\u00a0A (2020) Potential pharmacological approach in the regulation of ACE\u20112 and DPP-IV in diabetic COVID-19 patient. Ital J Med. https:\/\/doi.org\/10.4081\/itjm.2020.1435","journal-title":"Ital J Med"},{"key":"5142_CR30","doi-asserted-by":"publisher","first-page":"110486","DOI":"10.1016\/j.mehy.2021.110486","volume":"147","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, La Porta\u00a0R, Ferrara\u00a0F (2021) Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 147:110486. https:\/\/doi.org\/10.1016\/j.mehy.2021.110486","journal-title":"Med Hypotheses"},{"issue":"2","key":"5142_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","volume":"17","author":"M Paz Ocaranza","year":"2020","unstructured":"Paz Ocaranza\u00a0M, Riquelme\u00a0JA, Garc\u00eda\u00a0L, Jalil\u00a0JE, Chiong\u00a0M, Santos\u00a0RAS, Lavandero\u00a0S (2020) Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol 17(2):116\u2013129. https:\/\/doi.org\/10.1038\/s41569-019-0244-8","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"5142_CR32","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan\u00a0M, Vardeny\u00a0O, Michel\u00a0T, McMurray\u00a0JJV, Pfeffer\u00a0MA, Solomon\u00a0SD (2020) Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N\u00a0Engl J Med 382(17):1653\u20131659. https:\/\/doi.org\/10.1056\/NEJMsr2005760","journal-title":"N Engl J Med"},{"key":"5142_CR33","doi-asserted-by":"publisher","first-page":"173373","DOI":"10.1016\/j.ejphar.2020.173373","volume":"883","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F (2020) Correlation between renin-angiotensin system and severe acute respiratory syndrome Coronavirus 2 infection: what do we know? Eur J Pharmacol 883:173373. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173373","journal-title":"Eur J Pharmacol"},{"key":"5142_CR34","doi-asserted-by":"publisher","first-page":"118510","DOI":"10.1016\/j.lfs.2020.118510","volume":"262","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F (2020) Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 262:118510. https:\/\/doi.org\/10.1016\/j.lfs.2020.118510","journal-title":"Life Sci"},{"issue":"15","key":"5142_CR35","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1007\/s00018-007-6228-6","volume":"64","author":"Y Imai","year":"2007","unstructured":"Imai\u00a0Y, Kuba\u00a0K, Penninger\u00a0JM (2007) Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci 64(15):2006\u20132012","journal-title":"Cell Mol Life Sci"},{"key":"5142_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00407-9","author":"S Muslim","year":"2020","unstructured":"Muslim\u00a0S, Nasrin\u00a0N, Alotaibi\u00a0FO, Prasad\u00a0G, Singh\u00a0SK, Alam\u00a0I, Mustafa\u00a0G (2020) Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE\u20112, angiotensin (1\u20137) and angiotensin (1\u20139) as effective therapeutic measure. SN Compr Clin Med. https:\/\/doi.org\/10.1007\/s42399-020-00407-9","journal-title":"SN Compr Clin Med"},{"issue":"4","key":"5142_CR37","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil\u00a0V, Kwon\u00a0H, Prado\u00a0P, Hagelkr\u00fcys\u00a0A, Wimmer\u00a0RA, Stahl\u00a0M, Leopoldi\u00a0A, Garreta\u00a0E, Hurtado Del Pozo\u00a0C, Prosper\u00a0F, Romero\u00a0JP, Wirnsberger\u00a0G, Zhang\u00a0H, Slutsky\u00a0AS, Conder\u00a0R, Montserrat\u00a0N, Mirazimi\u00a0A, Penninger\u00a0JM (2020) Inhibition of SARS-CoV\u20112 infections in engineered human tissues using clinical-grade soluble human ACE\u20112. Cell 181(4):905\u2013913.e7. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004","journal-title":"Cell"},{"issue":"1","key":"5142_CR38","doi-asserted-by":"publisher","first-page":"e13426","DOI":"10.15252\/emmm.202013426","volume":"13","author":"V Monteil","year":"2021","unstructured":"Monteil\u00a0V, Dyczynski\u00a0M, Lauschke\u00a0VM, Kwon\u00a0H, Wirnsberger\u00a0G, Youhanna\u00a0S, Zhang\u00a0H, Slutsky\u00a0AS, Hurtado Del Pozo\u00a0C, Horn\u00a0M, Montserrat\u00a0N, Penninger\u00a0JM, Mirazimi\u00a0A (2021) Human soluble ACE\u20112 improves the effect of remdesivir in SARS-CoV\u20112 infection. EMBO Mol Med 13(1):e13426. https:\/\/doi.org\/10.15252\/emmm.202013426","journal-title":"EMBO Mol Med"},{"issue":"4","key":"5142_CR39","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s11845-020-02482-2","volume":"190","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F, La Porta\u00a0R (2021) Remdesivir and COVID-19 disease, therapeutic benefitsor unnecessary risks? Ir J Med Sci 190(4):1637\u20131638","journal-title":"Ir J Med Sci"},{"issue":"5","key":"5142_CR40","doi-asserted-by":"publisher","first-page":"R133","DOI":"10.1530\/EJE-20-0665","volume":"183","author":"JP Bilezikian","year":"2020","unstructured":"Bilezikian\u00a0JP, Bikle\u00a0D, Hewison\u00a0M, Lazaretti-Castro\u00a0M, Formenti\u00a0AM, Gupta\u00a0A, Madhavan\u00a0MV, Nair\u00a0N, Babalyan\u00a0V, Hutchings\u00a0N, Napoli\u00a0N, Accili\u00a0D, Binkley\u00a0N, Landry\u00a0DW, Giustina\u00a0A (2020) Mechanisms in endocrinology: vitamin D and COVID-19. Eur J Endocrinol 183(5):R133\u2013R147. https:\/\/doi.org\/10.1530\/EJE-20-0665","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"5142_CR41","doi-asserted-by":"publisher","first-page":"e13513","DOI":"10.1111\/apha.13513","volume":"231","author":"A Marquez","year":"2021","unstructured":"Marquez\u00a0A, Wysocki\u00a0J, Pandit\u00a0J, Batlle\u00a0D (2021) An update on ACE\u20112 amplification and its therapeutic potential. Acta Physiol (Oxf) 231(1):e13513. https:\/\/doi.org\/10.1111\/apha.13513","journal-title":"Acta Physiol (Oxf)"},{"key":"5142_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/acsptsci.2c00003","volume":"5","author":"K Dutta","year":"2022","unstructured":"Dutta\u00a0K (2022) Allosteric site of ACE\u20112 as a\u00a0drug target for COVID-19. ACS Pharmacol Transl Sci 5:179\u2013182","journal-title":"ACS Pharmacol Transl Sci"},{"key":"5142_CR43","doi-asserted-by":"publisher","first-page":"710946","DOI":"10.3389\/fcvm.2021.710946","volume":"8","author":"L Huang","year":"2021","unstructured":"Huang\u00a0L, Chen\u00a0Z, Ni\u00a0L, Chen\u00a0L, Zhou\u00a0C, Gao\u00a0C, Wu\u00a0X, Hua\u00a0L, Huang\u00a0X, Cui\u00a0X et al (2021) Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the inflammatory response and viral clearance in COVID-19 patients. Front Cardiovasc Med 8:710946","journal-title":"Front Cardiovasc Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05142-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T12:02:47Z","timestamp":1695988967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05142-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5142"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05142-6","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"type":"print","value":"0340-9937"},{"type":"electronic","value":"1615-6692"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"29 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.\u00a0Vitiello, A.\u00a0Zovi, U.\u00a0Trama and F.\u00a0Ferrara declare that they have no competing interests. Consent to Publish: The authors consent to the publication of the manuscript. All authors declare that the opinions expressed are of a personal nature and their administrations are not responsible for this.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. Ethical Approval and Consent to Participate: Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}